Xultophy Quiz

Which of the following are part of the “ominous octet” associated with the pathogenesis of type 2 diabetes? Select all that apply

• Increase glucose reabsorption in the kidneys

• Decreased glucose uptake in the skeletal muscles

• Decreased lipolysis in the adipose tissue

• All of the above

Untreated hypoglycaemia may lead to

• Permanent cognitive impairment

• Loss of consciousness

• Death

• None of the above

The half-life of Insulin Degludec & Liraglutide respectively is

• 15.4 hrs & 3 mins

• 25.4 hrs & 13 hrs

• 35.4 hrs & 24 hrs

• 44.4 hrs & 19 hrs

The phase 3 trials of Insulin Degludec are collectively referred to as

• BOOST

• LEAD

• BEGIN

• DUAL

Liraglutide performs it’s action by binding to _____________ receptors

• G-Protein coupled receptors

• Muscarinic receptors

• Nicotinic receptors

• K-Protein coupled receptors

All the following T2DM therapies are weight neutral/providing weight benefit except

• DPP-4 inhibitors

• GLP-1 RAs

• Sulphonylureas

• SGLT-2 inhibitors

Liraglutide has 97% amino acid sequence identity to native human GLP-1compared with exenatide which has

• 90% homology

• 85% homology

• 50% homology

• 53% homology

The combination of Liraglutide & Insulin Degludec gives rise to which unique properties?

• Glycaemic control throughout the day

• Steady titration resulting in a more favourable tolerability profile

• Once daily administration, independent of meals in a single pen device

• a & c only

Compared with GLP-1 RA's, Xultophy offers

• Significantly better HbA1c reduction

• Similar rate of hypoglycaemia

• Similar weight loss

• None of the above

Dr Rauf Niazi recommend his patient switching to IDegLira because of its insulin sparing effect. What does he mean?

• His patient will never have to take insulin again

• His patient can use a lower dose of IDegLira but continue to gain weight

• His patient will achieve glycemic control with IDegLira but will have to add GLP-1 RA to his treatment

• His patient will achieve significant glycaemic control & weight benefits with/at a lower dose of IDegLira than with his current basal insulin therapy